California Cancer Registry faces funding crisis as experts urge legislative action

On March 6, 2023, the Assembly Budget Subcommittee No. 1 on Health and Human Services convened to discuss critical funding issues affecting the California Cancer Registry (CCR). The meeting highlighted the potential consequences of budget shortfalls on cancer research and health equity in the state.

Dr. Allison Curian, a professor at Stanford University and an oncologist, testified remotely about the CCR's vital role in tracking cancer cases across California. She emphasized that the registry is essential for understanding cancer's impact on diverse populations and for guiding research that addresses health disparities. Dr. Curian warned that the CCR is facing significant funding challenges, primarily due to declining revenues from Proposition 99, California's tobacco tax, which has historically supported the registry. She noted that the CCR is projected to experience a shortfall of nearly $1 million in the upcoming fiscal year, which could jeopardize its operations and the quality of data collected.

The California Department of Public Health (CDPH) echoed Dr. Curian's concerns, revealing that the CCR is expected to receive $10.6 million in funding for the fiscal year 2023-24, but faces a $750,000 shortfall necessary to maintain federal funding levels. The CDPH explained that the CCR relies on a combination of state and federal resources, and without adequate funding, the integrity and accuracy of cancer data could be compromised. This would hinder research efforts and potentially lead to a loss of up to $15.7 million in federal funding.

The discussions underscored the importance of the CCR not only for cancer research but also for ensuring equitable access to cancer care. Assembly members expressed their commitment to finding solutions to the funding crisis, recognizing that the CCR is a critical resource for understanding and addressing disparities in cancer treatment and outcomes.

As the committee prepares for the May revision of the budget, the urgency to secure stable funding for the CCR remains a priority. The outcome of these discussions will have significant implications for cancer research and public health initiatives in California, particularly for vulnerable communities disproportionately affected by cancer.